Drug Profile

Sparsentan - Travere Therapeutics

Alternative Names: DARA; FILSPARI; PS-433540; RE-021

Latest Information Update: 08 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bristol-Myers Squibb
Developer Chugai Pharmaceutical; CSL Vifor; Retrophin; Travere Therapeutics
Class Anti-inflammatories; Antihypertensives; Isoxazoles; Nerve growth factors; Small molecules; Spiro compounds; Sulfonamides; Urologics; Vascular disorder therapies
Mechanism of Action Angiotensin type 2 receptor antagonists; Endothelin A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - IgA nephropathy; Focal segmental glomerulosclerosis
New Molecular Entity Yes

Marketed IgA nephropathy
Registered Focal segmental glomerulosclerosis
Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis; Hereditary nephritis; Vasculitis
Discontinued Hypertension

02 Oct 2026 Updated efficacy data from the phase II SPARTAN trial in IgA nephropathy released by Travere Therapeutics
23 Sep 2026 Travere Therapeutics receives patent allowance for Sparsentan for Focal segmental glomerulosclerosis in USA
19 Aug 2026 Travere Therapeutics completes the phase-III PROTECT clinical trial in IgA nephropathy in USA, Australia, Belgium, France, Germany, Hong Kong, Italy, South Korea, New Zealand, Portugal, Poland, Taiwan, United Kingdom, Lithuania, Czech Republic, Croatia, Spain, and Estonia (PO) (NCT03762850) (ACTRN12618001511224) (EudraCT-2017-004605-41)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com